Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faldaprevir + TD-6450 + ribavirin
- Development stage
- Phase 2
- Lead developer
- Trek Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a direct-acting antiviral **triple drug combination** composed of faldaprevir (an NS3/4A protease inhibitor), TD-6450 (an NS5A inhibitor), and ribavirin (a nucleoside analogue). The regimen was developed and clinically tested by Trek Therapeutics for the treatment of chronic hepatitis C virus (HCV) infection, specifically in genotypes 1b and 4. Faldaprevir directly inhibits the NS3/4A protease, essential for viral replication, while TD-6450 blocks the NS5A protein required for both viral RNA replication and assembly, and ribavirin acts as a broad-spectrum antiviral likely through inhibition of inosine monophosphate dehydrogenase and RNA mutagenesis. Clinical trials demonstrated high sustained virologic response (SVR) rates in treated patients with good tolerability[1][2][3][4][6].
- Other names
- FDV + TD-6450 + RBV
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on faldaprevir + TD-6450 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faldaprevir + TD-6450 + ribavirin.